Recent Analysts’ Ratings Updates for Praxis Precision Medicines (PRAX)

A number of research firms have changed their ratings and price targets for Praxis Precision Medicines (NASDAQ: PRAX):

• 10/6/2026 – Praxis Precision Medicines had its “buy” rating reaffirmed by HC Wainwright. They now have a $1,201.00 price target on the stock.
• 10/6/2026 – Praxis Precision Medicines had its price target raised by BTIG Research from $810.00 to $826.00. They now have a “buy” rating on the stock.
• 9/24/2026 – Praxis Precision Medicines had its “buy” rating reaffirmed by HC Wainwright. They now have a $1,201.00 price target on the stock.
• 9/24/2026 – Praxis Precision Medicines had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $582.00 price target on the stock.
• 8/24/2026 – Praxis Precision Medicines had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 8/21/2026 – Praxis Precision Medicines had its “buy” rating reaffirmed by The Goldman Sachs Group, Inc.. They now have a $575.00 price target on the stock, up from $470.00.
• 8/17/2026 – Praxis Precision Medicines had its “strong-buy” rating reaffirmed by Raymond James Financial, Inc.. They now have a $945.00 price target on the stock.
• 8/8/2026 – Praxis Precision Medicines was upgraded by Wall Street Zen from “sell” to “hold”.
• 8/7/2026 – Praxis Precision Medicines had its “outperform” rating reaffirmed by Royal Bank Of Canada. They now have a $462.00 price target on the stock, up from $449.00.
• 8/7/2026 – Praxis Precision Medicines was given a new $514.00 price target by Robert W. Baird.
• 8/7/2026 – Praxis Precision Medicines had its “positive” rating reaffirmed by Wells Fargo & Company. They now have a $362.00 price target on the stock, up from $323.00.

Praxis Precision Medicines, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders. The company uses insights from human genetics, neuroscience and its Cerebrum™ platform to identify and advance medicines for conditions in which existing treatment options may be limited.

Praxis’ pipeline has included investigational treatments for epilepsies and other neurological disorders, including developmental and epileptic encephalopathies, essential tremor and movement-related conditions.